PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Merck
CETP Inhibitors: Blockbusters that Never Ran?
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, R&D, Technology, leadership Also tagged Biotech, Biotechnology and Pharmaceuticals, Cardiovascular disease, CETP Inhibitors, Lilly, Resverlogix, Roche Leave a comment
Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday
R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, Market Access, R&D, Strategy, leadership, pricing Also tagged Medco, payers, Prix Galien, reimbursement Leave a comment
Merck Gets to the Heart of the Matter
Merck may have succeeded in making a molecule that increases “good cholesterol,” which is likely the only real breakthrough left in the anti-cholesterol and hypertension market.
It has long been known that elevated LDL cholesterol and reduced HDL cholesterol are major risk factors for developing cardiovascular disease. And while much ado has been made about a [...]
Merck to Close Eight Plants
Image by Getty Images via @daylife
Over the next two years, Merck will shut down eight manufacturing plants, as well as eight research sites, as part of the ongoing Schering-Plough merger process. The company said in a statement that the various site exits will help “create a flexible R&D organization.”
Taking a page out of Pfizer’s book [...]
Posted in Strategy Also tagged business, Canada, Factory, Infectious disease, Research and development, Schering Plough, South America 3 Comments
Diabetes Drug Launch 2012: Tip-tops and Promo-flops